12 / 32
STAMPEDE: OS “AA+P comparison”
By metastatic status – pre-planned analysis
•
No evidence of nonproportional hazards (P = 0.31) or of heterogeneity of the treatment effect
•
Preplanned subgroup analysis:
•
M1 disease: 368 deaths
•
M0 disease: 78 deaths (immature)
ADT alone
ADT+AA+P
HR
0.61
95% CI
0.49 to 0.75
ADT alone
ADT+AA+P
HR
0.75
95% CI
0.48 to 1.18
M1 Disease
M0 Disease
James N et al. J Clin Oncol 2017;35(15):LBA5003 (suppl)
James N et al. N Engl J Med 2017;377(4):338-351
STAMPEDE: OS “AA+P comparison”
By metastatic status – pre-planned analysis
•
No vidence of nonproportional hazards (P = 0.31) or of heterogeneity of
•
Preplanned subgroup analysis:
•
M1 disease: 368 deaths
•
M0 disease: 78 deaths (immature)
ADT alone
ADT+AA+P
HR
0.61
95% CI
0.49 to 0.75
HR
95% CI
M1 Disease
M0
James N et al. J Clin On
James N et al. N